Exact Sciences Corp. (NASDAQ:EXAS) was up 4.5% during trading on Monday . The stock traded as high as $18.79 and last traded at $18.17, with a volume of 4,749,224 shares. The stock had previously closed at $17.38.

Several equities research analysts have recently commented on EXAS shares. Mizuho reiterated a “hold” rating and set a $6.50 price target on shares of Exact Sciences Corp. in a research report on Wednesday, June 15th. Craig Hallum upgraded shares of Exact Sciences Corp. from a “hold” rating to a “buy” rating and lifted their price target for the stock from $6.00 to $18.00 in a research report on Thursday, June 16th. Zacks Investment Research upgraded shares of Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Friday, July 29th. Canaccord Genuity reiterated a “buy” rating and set a $12.00 price target (up previously from $9.00) on shares of Exact Sciences Corp. in a research report on Wednesday, June 15th. Finally, Jefferies Group reissued a “buy” rating and set a $13.00 price objective on shares of Exact Sciences Corp. in a research note on Wednesday, June 15th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $15.54.

The firm’s market cap is $1.75 billion. The company has a 50 day moving average price of $12.72 and a 200 day moving average price of $8.04.

Exact Sciences Corp. (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, July 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.09. During the same period in the prior year, the company earned ($0.44) EPS. The firm earned $21.20 million during the quarter, compared to analyst estimates of $18.54 million. The business’s quarterly revenue was up 161.7% compared to the same quarter last year. On average, equities research analysts forecast that Exact Sciences Corp. will post ($1.81) EPS for the current year.

In other news, COO Maneesh Arora sold 7,359 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $14.82, for a total value of $109,060.38. Following the completion of the transaction, the chief operating officer now owns 538,736 shares of the company’s stock, valued at $7,984,067.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Graham Peter Lidgard sold 7,383 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $14.82, for a total value of $109,416.06. Following the completion of the transaction, the insider now directly owns 227,592 shares of the company’s stock, valued at approximately $3,372,913.44. The disclosure for this sale can be found here.

A number of hedge funds have recently added to or reduced their stakes in EXAS. US Bancorp DE increased its stake in Exact Sciences Corp. by 2.3% in the fourth quarter. US Bancorp DE now owns 229,594 shares of the company’s stock worth $2,119,000 after buying an additional 5,109 shares in the last quarter. California State Teachers Retirement System increased its stake in Exact Sciences Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 177,702 shares of the company’s stock worth $1,640,000 after buying an additional 2,809 shares in the last quarter. Finally, Eagle Asset Management purchased a new stake in Exact Sciences Corp. during the third quarter worth $39,880,000.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.